The proteasome inhibitor, bortezomib, induces prostate cancer cell death by suppressing the expression of prostate-specific membrane antigen, as well as androgen receptor

Kuroda,Kenji; Liu,He

doi:10.3892/ijo.2019.4706

The proteasome inhibitor, bortezomib, induces prostate cancer cell death by suppressing the expression of prostate-specific membrane antigen, as well as androgen receptor

Authors:
- Kenji Kuroda
- He Liu
View Affiliations

Affiliations: Department of Urology, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan, Laboratory of Urological Oncology, Department of Urology, Weill Cornell Medical College, New York, NY 10065, USA
Published online on: February 1, 2019 https://doi.org/10.3892/ijo.2019.4706
Pages: 1357-1366

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The progression of primary prostate cancer (PC) is dependent on the androgen receptor (AR) and prostate‑specific membrane antigen (PSMA). Furthermore, the growth of PC cells is terminated with the downregulation of both AR and PSMA. In our preliminary experiments, it was also found that bortezomib (BZ; PS‑341) that inhibits 26S proteasome activity, acts as a downregulator of both PSMA and AR. In addition to evaluating the effects of BZ on protein expression, the present study evaluated and compared the anticancer effects of BZ on the growth of cells treated with BZ, docetaxel (DOC), or a combination of both. Western blot analysis was used to examine the expression levels of AR and PSMA. The knockdown effect of small interfering RNA (siRNA) and the drugs on the expression of either AR or PSMA was also evaluated. An MTT assay was performed in order to evaluate the inhibitory effects of the drugs on PC cells. The cell cycles were analyzed, and apoptotic cells were detected. The downregulation of AR and PSMA was observed using siRNA specific to AR or PSMA, and the inhibition of PSMA, as well as that of AR severely suppressed the growth of PC cells. The inhibitory effect of BZ alone on PSMA expression was similar to that of both AR‑ and PSMA‑specific siRNA, and this drug also induced the downregulation of AR and PSMA in PC cells. This phenomenon was confirmed even in cells transfected to overexpress PSMA. The apoptosis‑promoting effect of BZ on the cells was similar to that observed with BZ plus DOC, and more potent than that of DOC alone. BZ had the same inhibitory effect on the expression of AR and PSMA as did siRNA specific to AR or PSMA. On the whole, the findings of this study indicate that BZ may prove to be a promising chemotherapeutic agent and may be used as a molecularly targeted drug in the treatment of PC.

View Figures

View References

1	Huggins C and Hodges CV; Studies on prostatic cancer: I The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate CA. Cancer J Clin. 22:232–240. 1972. View Article : Google Scholar
2	Brawer MK, Crawford ED, Labrie F, Mendoza-Valdes A, Miller PDPD and Petrylak DP: Androgen deprivation and other treatments for advanced prostate cancer. Rev Urol. 3(Suppl 2): S59–S68. 2001.
3	Labrie F: Medical castration with LHRH agonists: 25 years later with major benefits achieved on survival in prostate cancer. J Androl. 25:305–313. 2004. View Article : Google Scholar : PubMed/NCBI
4	Feldman BJ and Feldman D: The development of androgen-independent prostate cancer. Nat Rev Cancer. 1:34–45. 2001. View Article : Google Scholar
5	Ross JS, Sheehan CE, Fisher HAG, Kaufman RP Jr, Kaur P, Gray K, Webb I, Gray GS, Mosher R and Kallakury BV: Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res. 9:6357–6362. 2003.PubMed/NCBI
6	Wright GL Jr, Grob BM, Haley C, Grossman K, Newhall K, Petrylak D, Troyer J, Konchuba A, Schellhammer PF and Moriarty R: Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology. 48:326–334. 1996. View Article : Google Scholar : PubMed/NCBI
7	Chang SS, Keefe DS, Bacich DJ, Reuter VE, Heston WD and Gaudin PB: Advances in brief prostate-specific membrane antigen is produced in tumor. Clin Cancer Res. 5:2674–2681. 1999.PubMed/NCBI
8	Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V, Knudsen B and Bander NH: Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res. 57:3629–3634. 1997.PubMed/NCBI
9	Adams J: Proteasome inhibitors as new anticancer drugs. Curr Opin Oncol. 14:628–634. 2002. View Article : Google Scholar : PubMed/NCBI
10	LeBlanc R, Catley LP, Hideshima T, Lentzsch S, Mitsiades CS, Mitsiades N, Neuberg D, Goloubeva O, Pien CS, Adams J, et al: Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 62:4996–5000. 2002.PubMed/NCBI
11	Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, Munshi N, Dang L, Castro A, Palombella V, et al: NF-κB as a therapeutic target in multiple myeloma. J Biol Chem. 277:16639–16647. 2002. View Article : Google Scholar : PubMed/NCBI
12	Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Treon SP, et al: Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA. 99:14374–14379. 2002. View Article : Google Scholar : PubMed/NCBI
13	Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S, Adams J, Esseltine DL, Elliott PJ, Pien CS, et al: Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol. 20:4420–4427. 2002. View Article : Google Scholar : PubMed/NCBI
14	Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, et al: The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: Therapeutic applications. Blood. 101:2377–2380. 2003. View Article : Google Scholar
15	Ma MH, Yang HH, Parker K, Manyak S, Friedman JM, Altamirano C, Wu ZQ, Borad MJ, Frantzen M, Roussos E, et al: The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res. 9:1136–1144. 2003.PubMed/NCBI
16	Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J and Anderson KC: The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 61:3071–3076. 2001.PubMed/NCBI
17	Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, et al: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 348:2609–2617. 2003. View Article : Google Scholar : PubMed/NCBI
18	Kuroda K, Liu H, Kim S, Guo M, Navarro V and Bander NH: Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: Implications for PSA surrogacy. Prostate. 69:1579–1585. 2009. View Article : Google Scholar : PubMed/NCBI
19	Compagno D, Merle C, Morin A, Gilbert C, Mathieu JR, Bozec A, Mauduit C, Benahmed M and Cabon F: SIRNA-directed in vivo silencing of androgen receptor inhibits the growth of castration-resistant prostate carcinomas. PLoS One. 2:e10062007. View Article : Google Scholar : PubMed/NCBI
20	Lee UJ, Choung SR, Prakash KV, Lee EJ, Lee MY, Kim YJ, Han CW and Choi YC: Dual knockdown of p65 and p50 subunits of NF-kappaB by siRNA inhibits the induction of inflammatory cytokines and significantly enhance apoptosis in human primary synoviocytes treated with tumor necrosis factor-alpha. Mol Biol Rep. 35:291–298. 2008. View Article : Google Scholar
21	Israeli RS, Powell CT, Corr JG, Fair WR and Heston WD: Expression of the prostate-specific membrane antigen. Cancer Res. 54:1807–1811. 1994.PubMed/NCBI
22	Kuroda K, Liu H, Kim S, Guo M, Navarro V and Bander NH: Saporin toxin-conjugated monoclonal antibody targeting prostate-specific membrane antigen has potent anticancer activity. Prostate. 70:1286–1294. 2010.PubMed/NCBI
23	Bravaccini S, Puccetti M, Bocchini M, Ravaioli S, Celli M, Scarpi E, De Giorgi U, Tumedei MM, Raulli G, Cardinale L, et al: PSMA expression: A potential ally for the pathologist in prostate cancer diagnosis. Sci Rep. 8:42542018. View Article : Google Scholar : PubMed/NCBI
24	Minner S, Wittmer C, Graefen M, Salomon G, Steuber T, Haese A, Huland H, Bokemeyer C, Yekebas E, Dierlamm J, et al: High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer. Prostate. 71:281–288. 2011. View Article : Google Scholar
25	Khurana N, Talwar S, Chandra PK, Sharma P, Abdel-Mageed AB, Mondal D and Sikka SC: Sulforaphane increases the efficacy of anti-androgens by rapidly decreasing androgen receptor levels in prostate cancer cells. Int J Oncol. 49:1609–1619. 2016. View Article : Google Scholar : PubMed/NCBI
26	Komura K, Jeong SH, Hinohara K, Qu F, Wang X, Hiraki M, Azuma H, Lee GS, Kantoff PW and Sweeney CJ: Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression. Proc Natl Acad Sci USA. 113:6259–6264. 2016. View Article : Google Scholar
27	Williams S, Pettaway C, Song R, Papandreou C, Logothetis C and McConkey DJ: Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol Cancer Ther. 2:835–843. 2003.PubMed/NCBI
28	Papandreou CN and Logothetis CJ: Bortezomib as a potential treatment for prostate cancer. Cancer Res. 64:5036–5043. 2004. View Article : Google Scholar : PubMed/NCBI
29	Codony-Servat J, Tapia MA, Bosch M, Oliva C, Domingo-Domenech J, Mellado B, Rolfe M, Ross JS, Gascon P, Rovira A, et al: Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells. Mol Cancer Ther. 5:665–675. 2006. View Article : Google Scholar : PubMed/NCBI
30	Lohiya V, Aragon-Ching JB and Sonpavde G: Role of chemotherapy and mechanisms of resistance to chemotherapy in metastatic castration-resistant prostate cancer. Clin Med Insights Oncol. 10(Suppl 1): 57–66. 2016.PubMed/NCBI
31	Aras B and Yerlikaya A: Bortezomib and etoposide combinations exert synergistic effects on the human prostate cancer cell line PC-3. Oncol Lett. 11:3179–3184. 2016. View Article : Google Scholar : PubMed/NCBI
32	Cao W, Shiverick KT, Namiki K, Sakai Y, Porvasnik S, Urbanek C and Rosser CJ: Docetaxel and bortezomib downregulate Bcl-2 and sensitize PC-3-Bcl-2 expressing prostate cancer cells to irradiation. World J Urol. 26:509–516. 2008. View Article : Google Scholar : PubMed/NCBI
33	Christian PA, Thorpe JA and Schwarze SR: Velcade sensitizes prostate cancer cells to TRAIL induced apoptosis and suppresses tumor growth in vivo. Cancer Biol Ther. 8:73–80. 2009. View Article : Google Scholar
34	Thorpe JA, Christian PA and Schwarze SR: Proteasome inhibition blocks caspase-8 degradation and sensitizes prostate cancer cells to death receptor-mediated apoptosis. Prostate. 68:200–209. 2008. View Article : Google Scholar
35	Janyst K, Janyst M, Siernicka M and Lasek W: Synergistic antitumor effects of histone deacetylase inhibitor scriptaid and bortezomib against ovarian cancer cells. Oncol Rep. 39:1999–2005. 2018.PubMed/NCBI
36	Iida S, Ichinohe T, Shinagawa A, Suzuki K, Takezako N and Aoki M: Safety and efficacy of daratumumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma. Int J Hematol. 107:460–467. 2018. View Article : Google Scholar
37	Wehenkel M, Ban JO, Ho YK, Carmony KC, Hong JT and Kim KB: A selective inhibitor of the immunoproteasome subunit LMP2 induces apoptosis in PC-3 cells and suppresses tumour growth in nude mice. Br J Cancer. 107:53–62. 2012. View Article : Google Scholar : PubMed/NCBI
38	Kraft AS, Garrett-Mayer E, Wahlquist AE, Golshayan A, Chen CS, Butler W, Bearden J and Lilly M: Combination therapy of recurrent prostate cancer with the proteasome inhibitor bortezomib plus hormone blockade. Cancer Biol Ther. 12:119–124. 2011. View Article : Google Scholar : PubMed/NCBI
39	Hainsworth JD, Meluch AA, Spigel DR, Barton J Jr, Simons L, Meng C, Gould B and Greco FA: Weekly docetaxel and bortezomib as first-line treatment for patients with hormone-refractory prostate cancer: A Minnie Pearl Cancer Research Network phase II trial. Clin Genitourin Cancer. 5:278–283. 2007. View Article : Google Scholar : PubMed/NCBI